The firm anticipates that the award will accelerate the development of its over-the-counter and professional-use influenza and multiplex respiratory pathogen tests.
The firm said it will offer 4.5 million shares of its common stock at $20 per share. It expects to close its follow-on public offering on July 16.
OrigiMed is a Shanghai, China-based company focusing on the development of new oncology assays.
The latest round, led by Northpond Ventures, brings the total amount raised by the
company to date to $76 million.
The firm will use the proceeds to accelerate commercialization and deployment of its microfluidic technology and for working capital purposes.
Net proceeds from the exercise of subscription rights and warrants are anticipated to be $22.6 million, excluding any proceeds from the exercise of warrants.
The molecular diagnostics company previously raised $180 million in its 2015 initial public offering.
It anticipates using the funds to complete the development of its first set of diagnostic products, and for a set of clinical studies to obtain regulatory clearance.
The PGx decision support software that Sonic is adopting includes clinical reporting for 65 genes and can be tailored to a variety of clinical specialties.
The companies will combine their respective services into a single end-to-end offering for microbiome research.
Analyst Puneet Souda said HTG has a growing funnel of biopharma projects that have the potential to convert to companion diagnostics with regulatory approval.
The Beijing-based firm said it will use the funding for research and development, to obtain additional intellectual property, and to pursue its strategic goals.
The Slovenia-based firm will use the funds to develop its Health Intelligence platform, expand into Asian markets, and open an office in the UK.
The deal gives Biodesix an additional test in the lung cancer space, Indi's XL2, which helps to classify lung nodules identified by imaging scans as benign or malignant.
The center is an international joint venture established in 2013 between South Korean clinical lab Eone Life Science and California-based Diagnomics.
Under the new collaboration, Predicine will use its GeneRADAR technology to aid Kintor in the development and advancement of novel drugs.
MGI received medical device certification clearance for its MGISEQ-200 and MGISEQ-2000 instruments.
The deal covers MNG's complete line of neurogenetic clinical RNA sequencing services, including complete transcriptome sequencing.
The partners are aiming to generate proteomic and phosphoproteomic data that they can include in Indivumed's global cancer database.
Finland-based Tieto and Swiss firm BC Platforms will jointly develop technology for integrating genomic and clinical data in the Northern European market.
With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.
NPR reports that government and private insurers are being slow to cover recently approved CAR-T cell therapies.
CNBC reports that there are thousands of genetic tests available for consumers to chose between.
In Nature this week: genomic analysis of ducks, whole-genome doubling among tumor samples, and more.